Viewpoints

Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone
23 Oct 2020

Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone

Zoliflodacin is an oral antibiotic with a novel mode of action distinct from quinolones. The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin in a phase 2 study conducted in the U.S. Zoliflodacin offers many of the WHO preferred characteristics for gonorrhoea therapy, including single dose therapy, low rate of side effects, and both urogenital and extragenital site efficacy.

Read more
We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.